Loading...

NanoRepro AG

NN6.DEXETRA
Healthcare
Medical - Diagnostics & Research
1.58
0.03(2.26%)
German Market is Open • 13:01

NanoRepro AG Fundamental Analysis

NanoRepro AG (NN6.DE) shows weak financial fundamentals with a PE ratio of -11.16, profit margin of -33.37%, and ROE of -4.57%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position37.90%
PEG Ratio-0.89
Current Ratio32.12

Areas of Concern

ROE-4.57%
Operating Margin-44.77%
We analyze NN6.DE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
0.9/100

We analyze NN6.DE's fundamental strength across five key dimensions:

Efficiency Score

Weak

NN6.DE struggles to generate sufficient returns from assets.

ROA > 10%
-4.54%

Valuation Score

Excellent

NN6.DE trades at attractive valuation levels.

PE < 25
-11.16
PEG Ratio < 2
-0.89

Growth Score

Weak

NN6.DE faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

NN6.DE maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
32.12

Profitability Score

Weak

NN6.DE struggles to sustain strong margins.

ROE > 15%
-457.07%
Net Margin ≥ 15%
-33.37%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is NN6.DE Expensive or Cheap?

P/E Ratio

NN6.DE trades at -11.16 times earnings. This suggests potential undervaluation.

-11.16

PEG Ratio

When adjusting for growth, NN6.DE's PEG of -0.89 indicates potential undervaluation.

-0.89

Price to Book

The market values NanoRepro AG at 0.52 times its book value. This may indicate undervaluation.

0.52

EV/EBITDA

Enterprise value stands at -12.26 times EBITDA. This is generally considered low.

-12.26

How Well Does NN6.DE Make Money?

Net Profit Margin

For every $100 in sales, NanoRepro AG keeps $-33.37 as profit after all expenses.

-33.37%

Operating Margin

Core operations generate -44.77 in profit for every $100 in revenue, before interest and taxes.

-44.77%

ROE

Management delivers $-4.57 in profit for every $100 of shareholder equity.

-4.57%

ROA

NanoRepro AG generates $-4.54 in profit for every $100 in assets, demonstrating efficient asset deployment.

-4.54%

Following the Money - Real Cash Generation

Operating Cash Flow

NanoRepro AG generates strong operating cash flow of $2.84M, reflecting robust business health.

$2.84M

Free Cash Flow

NanoRepro AG generates strong free cash flow of $2.53M, providing ample flexibility for dividends, buybacks, or growth.

$2.53M

FCF Per Share

Each share generates $0.20 in free cash annually.

$0.20

FCF Yield

NN6.DE converts 13.18% of its market value into free cash.

13.18%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-11.16

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.89

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.52

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.72

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

32.12

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.05

vs 25 benchmark

ROA

Return on assets percentage

-0.05

vs 25 benchmark

ROCE

Return on capital employed

-0.06

vs 25 benchmark

How NN6.DE Stacks Against Its Sector Peers

MetricNN6.DE ValueSector AveragePerformance
P/E Ratio-11.1629.17 Better (Cheaper)
ROE-4.57%701.00% Weak
Net Margin-33.37%-43676.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio32.124.45 Strong Liquidity
ROA-4.54%-18965.00% (disorted) Weak

NN6.DE outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NanoRepro AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ